Therapix BioSciences, a biotech developing a portfolio of cannabinoid based therapies, filed on Friday with the SEC to raise up to $12 million in an initial public offering.
The Tel-Aviv, Israel-based company was founded in 2004. It plans to list on the Nasdaq under the symbol TRPX. Rodman & Renshaw is the sole bookrunner on the deal. No pricing terms were disclosed.
